Development of novel in vitro photosafety assays focused on the Keap1-Nrf2-ARE pathway.
Although photoallergens require UV energy for antigen formation, the subsequent immune response is considered to be the same as in ordinary skin sensitization. Therefore, in vitro tests for skin sensitization should also be applicable for photoallergy testing. In this study, we examined whether activation of the Keap1 (Kelch-like ECH-associated protein 1)-Nrf2 (nuclear factor-erythroid 2-related factor 2)-ARE (antioxidant response element) pathway could be used to assess the photoallergenic potential of chemicals, using the reporter cell line AREc32 or KeratinoSens(TM) . First, we identified an appropriate UVA irradiation dose [5 J cm(-2) irradiation in phosphate-buffered saline (PBS)] by investigating the effect of UV irradiation on ARE-dependent gene induction using untreated or 6-methylcoumarin (6-MC)-treated cells. Irradiation of well-known photoallergens under this condition increased ARE-dependent gene expression by more than 50% compared with both vehicle and non-irradiated controls. When the cut-off value for detecting photoallergens was set at 50% induction, the accuracy of predicting photoallergenic/phototoxic chemicals was 70% in AREc32 cells and 67% in KeratinoSens(TM) cells, and the specificity was 100% in each case. We designate these assays as a photo-ARE assay and photo-KeratinoSens(TM) , respectively. Our results suggest that activation of the Keap1-Nrf2-ARE pathway is an effective biomarker for evaluating both photoallergenic and phototoxic potentials. Either of the above tests might be a useful component of a battery of in vitro tests/in silico methods for predicting the photoallergenicity and phototoxicity of chemicals. Copyright © 2015 John Wiley & Sons, Ltd.
Shiseido Research Center, Shiseido Co. Ltd, 2-2-1 Hayabuchi, Tsuzuki-ku, Yokohama, Kanagawa, 224-8558, Japan.
Kyoko
K
Tsujita-Inoue
Shiseido Research Center, Shiseido Co. Ltd, 2-2-1 Hayabuchi, Tsuzuki-ku, Yokohama, Kanagawa, 224-8558, Japan.
Morihiko
M
Hirota
Shiseido Research Center, Shiseido Co. Ltd, 2-2-1 Hayabuchi, Tsuzuki-ku, Yokohama, Kanagawa, 224-8558, Japan.
Tomomi
T
Atobe
Shiseido Research Center, Shiseido Co. Ltd, 2-2-1 Hayabuchi, Tsuzuki-ku, Yokohama, Kanagawa, 224-8558, Japan.
Takao
T
Ashikaga
Department of Dermatology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka, 431-3192, Japan.
Yoshiki
Y
Tokura
Shiseido Research Center, Shiseido Co. Ltd, 2-2-1 Hayabuchi, Tsuzuki-ku, Yokohama, Kanagawa, 224-8558, Japan.
Hirokazu
H
Kouzuki
D000485:Allergens / Q000633:toxicity*; D061745:Antioxidant Response Elements; D045744:Cell Line, Tumor; D003374:Coumarins / Q000633:toxicity; D017484:Dermatitis, Phototoxic / Q000378:metabolism*; D004307:Dose-Response Relationship, Radiation; D005786:Gene Expression Regulation; D005819:Genetic Markers; D006801:Humans; D000072019:Kelch-Like ECH-Associated Protein 1 / Q000235:genetics / Q000378:metabolism*; D051267:NF-E2-Related Factor 2 / Q000235:genetics / Q000378:metabolism*; D012680:Sensitivity and Specificity; D015398:Signal Transduction; D014466:Ultraviolet Rays / Q000009:adverse effects*
D000485:Allergens; D003374:Coumarins; D005819:Genetic Markers; C431364:KEAP1 protein, human; D000072019:Kelch-Like ECH-Associated Protein 1; D051267:NF-E2-Related Factor 2; C495635:NFE2L2 protein, human; C018096:6-methylcoumarin
ARE; Keap1; KeratinoSensTM; Nrf; in vitro; photoallergy